Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status
Open accessThe DOI matches its Crossref record; 127 of the 127 references it cites were found in a registry or an index.
Abstract
The efficacy of standard antidepressants is limited for many patients with mood disorders such as major depressive disorder (MDD) and bipolar depression, underscoring the urgent need to develop novel therapeutics. Both clinical and preclinical studies have implicated glutamatergic system dysfunction in the pathophysiology of mood disorders. In particular, rapid reductions in depressive symptoms have been observed in response to subanesthetic doses of the glutamatergic modulator racemic (R,S)-ketamine in individuals with mood disorders. These results have prompted investigation into other glutamatergic modulators for depression, both as monotherapy and adjunctively. Several glutamate receptor-modulating agents have been tested in proof-of-concept studies for mood disorders. This manuscript gives a brief overview of the glutamate system and its relevance to rapid antidepressant response and discusses the existing clinical evidence for glutamate receptor-modulating agents, including (1) broad glutamatergic modulators ((R,S)-ketamine, esketamine, (R)-ketamine, (2R,6R)-hydroxynorketamine [HNK], dextromethorphan, Nuedexta [a combination of dextromethorphan and quinidine], deudextromethorphan [AVP-786], axsome [AXS-05], dextromethadone [REL-1017], nitrous oxide, AZD6765, CLE100, AGN-241751); (2) glycine site modulators (D-cycloserine [DCS], NRX-101, rapastinel [GLYX-13], apimostinel [NRX-1074], sarcosine, 4-chlorokynurenine [4-Cl-KYN/AV-101]); (3) subunit (NR2B)-specific N-methyl-D-aspartate (NMDA) receptor antagonists (eliprodil [EVT-101], traxoprodil [CP-101,606], rislenemdaz [MK-0657/CERC-301]); (4) metabotropic glutamate receptor (mGluR) modulators (basimglurant, AZD2066, RG1578, TS-161); and (5) mammalian target of rapamycin complex 1 (mTORC1) activators (NV-5138). Many of these agents are still in the preliminary stages of development. Furthermore, to date, most have demonstrated relatively modest effects compared with (R,S)-ketamine and esketamine, though some have shown more favorable characteristics. Of these novel agents, the most promising, and the ones for which the most evidence exists, appear to be those targeting ionotropic glutamate receptors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Glycine site modulators such as GLYX-13, apimostinel, and 4-Chlorokynurenine (AV-101) experienced similar difficulties [168]”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [168]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 1×
“5 mg/kg) infusion of the NMDA receptor antagonist (R,S)-ketamine given as monotherapy exerted antidepressant effects that began within 4 h of infusion and peaked at 72 h in a group of seven participants with major depression (seven with MDD and one with bipolar depression) [7].”
BackgroundA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766 · cited 2×
“A subsequent series of randomized controlled studies corroborated and extended these findings and identified a 24-hour response rate of > 70% to a single, monotherapeutic (R,S)-ketamine infusion in 18 participants with TRD; this response lasted one week or longer in some patients [8].”
BackgroundSelf-citationmTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 2×
“As noted above, mTORC1 has been implicated as a downstream pathway connecting glutamate modulation with the induction of neuroplastic processes [32].”
BackgroundSteroid hormone metabolites are barbiturate-like modulators of the GABA receptor
Majewska, M. D., Harrison, N. L., Schwartz, R. D., Barker, J. L., & Paul, S. M. (1986) · Science · doi:10.1126/science.2422758 · Cited by 2,225 · cited 1×
“Brexanolone (Zulresso), a neurosteroid derivative of allopregnanolone, acts as a positive allosteric modulator of GABAA receptor function [122]; in contrast to benzodiazepines, positive allosteric modulators bind and trigger the GABAA receptor to open more frequently or for longer periods, but they do not work indepen…”
BackgroundMoghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793 · cited 1×
“Disinhibition of the pyramidal neuron would thus result in a transient, but significant, increase of extracellular glutamate—sometimes referred to as a ‘glutamate burst’— which is thought to be critical for antidepressant response [28], though it remains unclear how the glutamate burst leads to antidepressant effects.”
BackgroundNMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609 · cited 2×
“While (R)-ketamine is a less potent NMDA receptor inhibitor [30, 72], initial animal studies found that it had greater and longer-lasting antidepressant-like properties than esketamine [30, 73–75].”
BackgroundSelf-citationMurrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205 · cited 1×
“Since then, most of the placebo-controlled, double-blind, randomized trials examining this agent have demonstrated the antidepressant efficacy of subanesthetic-dose (R,S)-ketamine in individuals with TRD [8, 40] as well as bipolar depression [41, 42].”
BackgroundMechanisms of ketamine action as an antidepressant
Zanos, P., & Gould, T. D. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.255 · Cited by 1,127 · cited 1×
“Theories posited to explain (R,S)-ketamine’s mechanism of action include (i) inhibition of NMDA receptor-mediated transmission at the synapse; (ii) direct inhibition of extrasynaptic NMDA receptors; (iii) inhibition of NMDA receptor-dependent bursting activity in the lateral habenula; and (iv) inhibition of NMDA recep…”
BackgroundPlacebo Response in Studies of Major Depression: Variable, Substantial, and Growing
Walsh, B. T., Seidman, S. N., Sysko, R., & Gould, M. (2002) · JAMA · doi:10.1001/jama.287.14.1840 · Cited by 1,109 · cited 1×
“In addition, placebo response rates are highly variable [132], difficult to predict, and can hinder drug development.”
BackgroundMaeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103 · cited 1×
“Thus, the prevailing hypotheses suggest direct and indirect antagonism at the NMDA receptor as well as AMPA throughput modulation [5, 35, 36] as the neurochemical substrate of antidepressant effects.”
BackgroundSelf-citationDiazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963 · cited 1×
“Since then, most of the placebo-controlled, double-blind, randomized trials examining this agent have demonstrated the antidepressant efficacy of subanesthetic-dose (R,S)-ketamine in individuals with TRD [8, 40] as well as bipolar depression [41, 42].”
BackgroundSelf-citationHasler, G., van der Veen, J. W., Tumonis, T., Meyers, N., Shen, J., & Drevets, W. C. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.2.193 · Cited by 846 · cited 2×
“Glutamate appears to be reduced in the dorsolateral prefrontal cortex (PFC) of individuals with MDD [19] as well as in other areas of the PFC, such as the dorsomedial and dorsoanterolateral PFC [20] and the anterior cingulate cortex [21]; increased glutamate levels have also been observed in the occipital cortex [22].”
BackgroundZarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.010 · Cited by 811 · cited 1×
“Since then, most of the placebo-controlled, double-blind, randomized trials examining this agent have demonstrated the antidepressant efficacy of subanesthetic-dose (R,S)-ketamine in individuals with TRD [8, 40] as well as bipolar depression [41, 42].”
BackgroundSelf-citationSubtype-Specific Alterations of γ-Aminobutyric Acid and Glutamatein Patients With Major Depression
Sanacora, G., Gueorguieva, R., Epperson, C. N., Wu, Y.-T., Appel, M., Rothman, D. L., Krystal, J. H., & Mason, G. F. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.7.705 · Cited by 796 · cited 1×
“Glutamate appears to be reduced in the dorsolateral prefrontal cortex (PFC) of individuals with MDD [19] as well as in other areas of the PFC, such as the dorsomedial and dorsoanterolateral PFC [20] and the anterior cingulate cortex [21]; increased glutamate levels have also been observed in the occipital cortex [22].”
BackgroundDaly, E. J., Trivedi, M. H., Janik, A., Li, H., Zhang, Y., Li, X., Lane, R., Lim, P., Duca, A. R., Hough, D., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.1189 · Cited by 795
Meltzer-Brody, S., Colquhoun, H., Riesenberg, R., Epperson, C. N., Deligiannidis, K. M., Rubinow, D. R., Li, H., Sankoh, A. J., Clemson, C., Schacterle, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31551-4 · Cited by 795 · cited 1×
“5 days) antidepressant properties in a number of placebo-controlled, double-blind, randomized trials [125, 126].”
BackgroundMurrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786
Functional antagonists at the NMDA receptor complex exhibit antidepressant actions
Trullas, R., & Skolnick, P. (1990) · European Journal of Pharmacology · doi:10.1016/0014-2999(90)90204-j · Cited by 785 · cited 2×
“In particular, (R,S)-ketamine is known to be a potent NMDA receptor antagonist, and this quality is believed to underlie its rapid antidepressant effects [25].”
BackgroundMcIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., Brietzke, E., Dodd, S., Gorwood, P., Ho, R., et al. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20081251 · Cited by 731
Self-citationDaly, E. J., Singh, J. B., Fedgchin, M., Cooper, K., Lim, P., Shelton, R. C., Thase, M. E., Winokur, A., Van Nueten, L., Manji, H., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3739 · Cited by 718
Wilkinson, S. T., Ballard, E. D., Bloch, M. H., Mathew, S. J., Murrough, J. W., Feder, A., Sos, P., Wang, G., Zarate, C. A., & Sanacora, G. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17040472 · Cited by 696
Self-citationSafety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression
aan het Rot, M., Collins, K. A., Murrough, J. W., Perez, A. M., Reich, D. L., Charney, D. S., & Mathew, S. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.08.038 · Cited by 690
Canuso, C. M., Singh, J. B., Fedgchin, M., Alphs, L., Lane, R., Lim, P., Pinter, C., Hough, D., Sanacora, G., Manji, H., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17060720 · Cited by 676
Antidepressant drugs act by directly binding to TRKB neurotrophin receptors
Casarotto, P. C., Girych, M., Fred, S. M., Kovaleva, V., Moliner, R., Enkavi, G., Biojone, C., Cannarozzo, C., Sahu, M. P., Kaurinkoski, K., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.034 · Cited by 663
Gaynes, B. N., Warden, D., Trivedi, M. H., Wisniewski, S. R., Fava, M., & Rush, A. J. (2009) · Psychiatric Services · doi:10.1176/ps.2009.60.11.1439 · Cited by 661 · cited 1×
“inhibitors [SSRIs] and serotonin-norepinephrine reuptake inhibitors [SNRIs], among others) initially revolutionized the treatment of depression, these treatments are not effective for all individuals with MDD [2].”
BackgroundSustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation
Moda-Sava, R. N., Murdock, M. H., Parekh, P. K., Fetcho, R. N., Huang, B. S., Huynh, T. N., Witztum, J., Shaver, D. C., Rosenthal, D. L., Alway, E. J., et al. (2019) · Science · doi:10.1126/science.aat8078 · Cited by 643 · cited 1×
“These converging mechanisms appear to induce rapid and sustained changes in synaptic plasticity that result in synaptic spine remodeling that, in turn, propagate (R,S)-ketamine’s antidepressant-like effects over time [37].”
BackgroundFeder, A., Parides, M. K., Murrough, J. W., Perez, A. M., Morgan, J. E., Saxena, S., Kirkwood, K., aan het Rot, M., Lapidus, K. A. B., Wan, L.-B., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.62 · Cited by 613 · cited 2×
“In addition to these robust antidepressant effects, a single subanesthetic-dose (R,S)-ketamine infusion has also been found to have significant and rapid (1–4 h) anti-suicidal ideation effects [48–53], anti-anhedonic properties [54, 55], and therapeutic potential in other disorders such as posttraumatic stress disorde…”
BackgroundR-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects
Yang, C., Shirayama, Y., Zhang, J.-C., Ren, Q., Yao, W., Ma, M., Dong, C., & Hashimoto, K. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.136 · Cited by 605
Ketamine: Teaching an Old Drug New Tricks
Kohrs, R., & Durieux, M. E. (1998) · Anesthesia & Analgesia · doi:10.1097/00000539-199811000-00039 · Cited by 604
Price, R. B., Nock, M. K., Charney, D. S., & Mathew, S. J. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.04.029 · Cited by 600
Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression.
Newport, D. J., Carpenter, L. L., McDonald, W. M., Potash, J. B., Tohen, M., Nemeroff, C. B., & The APA Council of Research Task Force on Novel Biomarkers and Treatments (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040465 · Cited by 598 · cited 1×
“Finally, a recent meta-analysis that included data drawn from the studies described above found that high-dose (1000 mg/day), but not low-dose (250 mg/day), DCS had acute antidepressant effects [46].”
A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders
Sanacora, G., Frye, M. A., McDonald, W., Mathew, S. J., Turner, M. S., Schatzberg, A. F., Summergrad, P., Nemeroff, C. B., & for the American Psychiatric Association (APA) Council of Research Task Force on Novel Biomarkers and Treatments (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.0080 · Cited by 576
Auer, D. P., Pütz, B., Kraft, E., Lipinski, B., Schill, J., & Holsboer, F. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00159-6 · Cited by 564 · cited 1×
“Glutamate appears to be reduced in the dorsolateral prefrontal cortex (PFC) of individuals with MDD [19] as well as in other areas of the PFC, such as the dorsomedial and dorsoanterolateral PFC [20] and the anterior cingulate cortex [21]; increased glutamate levels have also been observed in the occipital cortex [22].”
BackgroundDiazGranados, N., Ibrahim, L. A., Brutsche, N. E., Ameli, R., Henter, I. D., Luckenbaugh, D. A., Machado-Vieira, R., & Zarate, C. A. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05327blu · Cited by 564
Self-citationGlutamate as a therapeutic target in psychiatric disorders
Javitt, D. C. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001551 · Cited by 524 · cited 1×
“Over the last two decades, clinical and preclinical evidence has demonstrated that the glutamatergic system contributes to the pathophysiology of MDD as well as a number of other psychiatric disorders, such as schizophrenia, Alzheimer’s disease, and bipolar disorder, though these are not believed to share a common und…”
BackgroundAttenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism
Williams, N. R., Heifets, B. D., Blasey, C., Sudheimer, K., Pannu, J., Pankow, H., Hawkins, J., Birnbaum, J., Lyons, D. M., Rodriguez, C. I., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18020138 · Cited by 519 · cited 1×
“For example, the opioid system has been suggested as a potential target [38], though not all studies are in agreement.”
BackgroundPreskorn, S. H., Baker, B., Kolluri, S., Menniti, F. S., Krams, M., & Landen, J. W. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31818a6cea · Cited by 518 · cited 1×
“One placebo-controlled, doubleblind, randomized study investigated 30 individuals with TRD [111] who received 6 weeks of open-label paroxetine followed by a single CP-101,606 infusion plus paroxetine 40 mg/day for 30 days.”
BackgroundBrexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial.
Kanes, S., Colquhoun, H., Gunduz-Bruce, H., Raines, S., Arnold, R., Schacterle, A., Doherty, J., Epperson, C. N., Deligiannidis, K. M., Riesenberg, R., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31264-3 · Cited by 479 · cited 1×
“5 days) antidepressant properties in a number of placebo-controlled, double-blind, randomized trials [125, 126].”
BackgroundLener, M. S., Niciu, M. J., Ballard, E. D., Park, M., Park, L. T., Nugent, A. C., & Zarate, C. A. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.05.005 · Cited by 468 · cited 1×
“Though contemporaneous findings of effective glutamate and GABA modulating agents for depression may be coincidental, it is notable that the interaction and balance between excitatory glutamate and inhibitory GABA in corticolimbic systems has been implicated in the pathophysiology and treatment of depression [129, 130…”
BackgroundSelf-citationGrunebaum, M. F., Galfalvy, H. C., Choo, T.-H., Keilp, J. G., Moitra, V. K., Parris, M. S., Marver, J. E., Burke, A. K., Milak, M. S., Sublette, M. E., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17060647 · Cited by 431
Phillips, J. L., Norris, S., Talbot, J., Birmingham, M., Hatchard, T., Ortiz, A., Owoeye, O., Batten, L. A., & Blier, P. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18070834 · Cited by 418
Bahji, A., Vazquez, G. H., & Zarate, C. A. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.09.071 · Cited by 408 · cited 1×
“A recent meta-analysis suggests the need to compare these two agents head-to-head [68].”
BackgroundSelf-citationCortical GABAergic Dysfunction in Stress and Depression: New Insights for Therapeutic Interventions
Fogaça, M. V., & Duman, R. S. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00087 · Cited by 396 · cited 1×
“Though contemporaneous findings of effective glutamate and GABA modulating agents for depression may be coincidental, it is notable that the interaction and balance between excitatory glutamate and inhibitory GABA in corticolimbic systems has been implicated in the pathophysiology and treatment of depression [129, 130…”
BackgroundRandomized Controlled Crossover Trial of Ketamine in Obsessive-Compulsive Disorder: Proof-of-Concept
Rodriguez, C. I., Kegeles, L. S., Levinson, A., Feng, T., Marcus, S. M., Vermes, D., Flood, P., & Simpson, H. B. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.150 · Cited by 386
McGirr, A., Berlim, M. T., Bond, D. J., Fleck, M. P., Yatham, L. N., & Lam, R. W. (2015) · Psychological Medicine · doi:10.1017/s0033291714001603 · Cited by 373
Kishimoto, T., Chawla, J. M., Hagi, K., Zarate, C. A., Kane, J. M., Bauer, M., & Correll, C. U. (2016) · Psychological Medicine · doi:10.1017/s0033291716000064 · Cited by 359 · cited 1×
“One meta-analysis of nine randomized, placebo-controlled studies found that (R,S)-ketamine’s antidepressant effects after a single administration typically begin 40 min postinfusion, peak approximately 24 h later, and lose superiority to placebo 10–12 days post-infusion [43].”
BackgroundSelf-citationR (−)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine
Zhang, J.-C., Li, S.-X., & Hashimoto, K. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.11.033 · Cited by 357
Moriguchi, S., Takamiya, A., Noda, Y., Horita, N., Wada, M., Tsugawa, S., Plitman, E., Sano, Y., Tarumi, R., ElSalhy, M., et al. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0252-9 · Cited by 357 · cited 1×
“One meta-analysis and systematic review of 1H-proton magnetic resonance spectroscopy (MRS) studies concluded that decreased levels of glutamatergic metabolites in the medial frontal cortex were associated with the pathophysiology of depression [23].”
BackgroundOverview of glutamatergic neurotransmission in the nervous system
Niciu, M. J., Kelmendi, B., & Sanacora, G. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.08.008 · Cited by 329 · cited 1×
“The two main classes of glutamatergic receptors—ionotropic and metabotropic (mGluR)—consist of various subtype families based on structure, ion selectivity, and mechanism of action of downstream effectors [18].”
BackgroundWajs, E., Aluisio, L., Holder, R., Daly, E. J., Lane, R., Lim, P., George, J. E., Morrison, R. L., Sanacora, G., Young, A. H., et al. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19m12891 · Cited by 308 · cited 1×
“These issues remain a concern, particularly in the context of long-term (R,S)-ketamine/esketamine use, and suggest that the side effect, safety, and addiction profile of these agents should be explored in larger studies designed to better identify the limitations associated with long-term use [65, 66].”
BackgroundKetamine : "Teaching an old drug new tricks"
Pauw, N. D. (2010) · Submitted in 2010 · Cited by 304
Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial
Murrough, J. W., Soleimani, L., DeWilde, K. E., Collins, K. A., Lapidus, K. A., Iacoviello, B. M., Lener, M., Kautz, M., Kim, J., Stern, J. B., et al. (2015) · Psychological Medicine · doi:10.1017/s0033291715001506 · Cited by 297
Lally, N., Nugent, A. C., Luckenbaugh, D. A., Ameli, R., Roiser, J. P., & Zarate, C. A. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.105 · Cited by 271 · cited 1×
“In addition to these robust antidepressant effects, a single subanesthetic-dose (R,S)-ketamine infusion has also been found to have significant and rapid (1–4 h) anti-suicidal ideation effects [48–53], anti-anhedonic properties [54, 55], and therapeutic potential in other disorders such as posttraumatic stress disorde…”
BackgroundSelf-citationIntravenous arketamine for treatment-resistant depression: open-label pilot study
Leal, G. C., Bandeira, I. D., Correia-Melo, F. S., Telles, M., Mello, R. P., Vieira, F., Lima, C. S., Jesus-Nunes, A. P., Guerreiro-Costa, L. N. F., Marback, R. F., et al. (2021) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-020-01110-5 · Cited by 257 · cited 1×
“5 mg/ kg) had rapid and significant antidepressant effects, leading to a 20-point reduction in Montgomery-Åsberg Depression Rating Scale (MADRS) score at 24 h; the investigators noted only mild dissociative side effects after (R)-ketamine infusion [76].”
BackgroundZarate, C. A., Mathews, D., Ibrahim, L., Chaves, J. F., Marquardt, C., Ukoh, I., Jolkovsky, L., Brutsche, N. E., Smith, M. A., & Luckenbaugh, D. A. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.10.019 · Cited by 255 · cited 1×
“promising, though modest, antidepressant effects in early clinical studies [95].”
BackgroundSelf-citationAntidepressant Potential of (R)-Ketamine in Rodent Models: Comparison with (S)-Ketamine
Fukumoto, K., Toki, H., Iijima, M., Hashihayata, T., Yamaguchi, J.-I., Hashimoto, K., & Chaki, S. (2017) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.239228 · Cited by 252
Feder, A., Costi, S., Rutter, S. B., Collins, A. B., Govindarajulu, U., Jha, M. K., Horn, S. R., Kautz, M., Corniquel, M., Collins, K. A., et al. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20050596 · Cited by 246 · cited 2×
“In addition to these robust antidepressant effects, a single subanesthetic-dose (R,S)-ketamine infusion has also been found to have significant and rapid (1–4 h) anti-suicidal ideation effects [48–53], anti-anhedonic properties [54, 55], and therapeutic potential in other disorders such as posttraumatic stress disorde…”
BackgroundSanacora, G., Smith, M. A., Pathak, S., Su, H.-L., Boeijinga, P. H., McCarthy, D. J., & Quirk, M. C. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.130 · Cited by 236 · cited 1×
“A 3-week, placebo-controlled, phase IIb trial of repeated-dose adjunctive lanicemine (at daily doses of either 100 mg or 150 mg) in 34 participants with TRD then found that this agent’s antidepressant effects were not rapid [96].”
BackgroundReview of 1H magnetic resonance spectroscopy findings in major depressive disorder: A meta-analysis
Yildiz-Yesiloglu, A., & Ankerst, D. P. (2006) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2005.12.004 · Cited by 232 · cited 1×
“Glutamate appears to be reduced in the dorsolateral prefrontal cortex (PFC) of individuals with MDD [19] as well as in other areas of the PFC, such as the dorsomedial and dorsoanterolateral PFC [20] and the anterior cingulate cortex [21]; increased glutamate levels have also been observed in the occipital cortex [22].”
BackgroundTrial of SAGE-217 in Patients with Major Depressive Disorder
Gunduz-Bruce, H., Silber, C., Kaul, I., Rothschild, A. J., Riesenberg, R., Sankoh, A. J., Li, H., Lasser, R., Zorumski, C. F., Rubinow, D. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1815981 · Cited by 232
Nitrous Oxide for Treatment-Resistant Major Depression: A Proof-of-Concept Trial
Nagele, P., Duma, A., Kopec, M., Gebara, M. A., Parsoei, A., Walker, M., Janski, A., Panagopoulos, V. N., Cristancho, P., Miller, J. P., et al. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.11.016 · Cited by 230 · cited 1×
“In a placebo-controlled, double-blind, crossover pilot study, 20 individuals with TRD received an hour of adjunctive-use inhaled nitrous oxide (50% nitrous oxide and 50% oxygen) or placebo (50% nitrogen and 50% oxygen) during two treatment sessions separated by 1 week [94].”
MethodIbrahim, L., DiazGranados, N., Jolkovsky, L., Brutsche, N., Luckenbaugh, D. A., Herring, W. J., Potter, W. Z., & Zarate, C. A. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31825d70d6 · Cited by 220 · cited 1×
“The efficacy of orally administered rislenemdaz (4–8 mg/day for 12 days) monotherapy for TRD was assessed in a small, placebo-controlled, double-blind, randomized, crossover pilot study [112].”
MethodSelf-citationIadarola, N. D., Niciu, M. J., Richards, E. M., Vande Voort, J. L., Ballard, E. D., Lundin, N. B., Nugent, A. C., Machado-Vieira, R., & Zarate, C. A. (2015) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315579059 · Cited by 201
Self-citationMachado-Vieira, R., Salvadore, G., Luckenbaugh, D. A., Manji, H. K., & Zarate, C. A. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0610 · Cited by 195 · cited 1×
“In addition, these compounds often take weeks or months to reach full effectiveness, underscoring the critical need to develop more effective and rapid-acting interventions for MDD [3].”
BackgroundSelf-citationPRESKORN, S., MACALUSO, M., MEHRA, D. V., ZAMMIT, G., MOSKAL, J. R., & BURCH, R. M. (2015) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000462606.17725.93 · Cited by 193 · cited 1×
“One week post-administration, participants who received the 5 and 10 mg/kg doses of GLYX-13 had a significant antidepressant response, as assessed by the HAM-D, compared with placebo [105]; antidepressant effects manifested within 2 h.”
MethodCorreia-Melo, F. S., Leal, G. C., Vieira, F., Jesus-Nunes, A. P., Mello, R. P., Magnavita, G., Caliman-Fontes, A. T., Echegaray, M. V. F., Bandeira, I. D., Silva, S. S., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.11.086 · Cited by 193
Pharmacology of dextromethorphan: Relevance to dextromethorphan/quinidine (Nuedexta®) clinical use
Taylor, C. P., Traynelis, S. F., Siffert, J., Pope, L. E., & Matsumoto, R. R. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.04.010 · Cited by 186 · cited 1×
“Co-administration yields significantly greater dextromethorphan plasma concentrations and CNS bioavailability [83].”
BackgroundA randomized add-on trial of high-dose d-cycloserine for treatment-resistant depression
Heresco-Levy, U., Gelfin, G., Bloch, B., Levin, R., Edelman, S., Javitt, D. C., & Kremer, I. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000910 · Cited by 177 · cited 1×
“A subsequent double-blind, placebo-controlled, 6-week parallel group study enrolled 26 participants with TRD and assessed the efficacy of escalating dose-adjunctive DCS, up to 1000 mg/day [102].”
MethodGrunebaum, M. F., Ellis, S. P., Keilp, J. G., Moitra, V. K., Cooper, T. B., Marver, J. E., Burke, A. K., Milak, M. S., Sublette, M. E., Oquendo, M. A., et al. (2017) · Bipolar Disorders · doi:10.1111/bdi.12487 · Cited by 174
Wilkinson, S. T., & Sanacora, G. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2018.11.007 · Cited by 173 · cited 4×
“Wilkinson and Sanacora (2019) note that studies have attempted to constrain the heterogeneity of participant samples in order to limit placebo response, often by limiting participants to those with TRD [98].”
BackgroundInfluentialConvergent Mechanisms Underlying Rapid Antidepressant Action
Zanos, P., Thompson, S. M., Duman, R. S., Zarate, C. A., & Gould, T. D. (2018) · CNS Drugs · doi:10.1007/s40263-018-0492-x · Cited by 171
Self-citationGlutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments
Kadriu, B., Musazzi, L., Henter, I. D., Graves, M., Popoli, M., & Zarate, C. A. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy094 · Cited by 165 · cited 2×
“The glutamatergic system is also believed to be key to the mechanism of action underlying the rapid antidepressant effects associated with a number of novel agents [5], most notably the glutamatergic modulator racemic (R,S)ketamine.”
BackgroundSelf-citationNiciu, M. J., Henter, I. D., Luckenbaugh, D. A., Zarate, C. A., & Charney, D. S. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135950 · Cited by 161 · cited 1×
“These findings fundamentally altered our underlying perceptions of the pathophysiology of depression and refocused research interest on the glutamatergic system as a source for possible treatments [13, 14] as well as new biomarkers for depression [15, 16].”
BackgroundSelf-citationLumsden, E. W., Troppoli, T. A., Myers, S. J., Zanos, P., Aracava, Y., Kehr, J., Lovett, J., Kim, S., Wang, F.-H., Schmidt, S., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1816071116 · Cited by 158
Self-citationPharmacotherapy of Postpartum Depression: Current Approaches and Novel Drug Development
Frieder, A., Fersh, M., Hainline, R., & Deligiannidis, K. M. (2019) · CNS Drugs · doi:10.1007/s40263-019-00605-7 · Cited by 156 · cited 1×
“Brexanolone’s mechanism of rapid antidepressant action is presently unclear, but is thought to bind to both synaptic and extrasynaptic GABAA receptors, thus increasing receptor functionality [124].”
BackgroundInhibition of Glycine Transporter-I as a Novel Mechanism for the Treatment of Depression
Huang, C., Wei, I., Huang, C.-L., Chen, K.-T., Tsai, M., Tsai, P., Tun, R., Huang, K.-H., Chang, Y., Lane, H., et al. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.02.020 · Cited by 152 · cited 2×
“Sarcosine-treated patients were also less likely to drop out of the study (30% vs 45% for sarcosine vs citalopram, respectively) [108].”
BackgroundResult( 2R,6R )-hydroxynorketamine exerts mGlu 2 receptor-dependent antidepressant actions
Zanos, P., Highland, J. N., Stewart, B. W., Georgiou, P., Jenne, C. E., Lovett, J., Morris, P. J., Thomas, C. J., Moaddel, R., Zarate, C. A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819540116 · Cited by 152
Self-citationMeta-analysis of short- and mid-term efficacy of ketamine in unipolar and bipolar depression
Romeo, B., Choucha, W., Fossati, P., & Rotge, J.-Y. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.10.032 · Cited by 151
Antidepressant actions of ketamine engage cell-specific translation via eIF4E
Aguilar-Valles, A., De Gregorio, D., Matta-Camacho, E., Eslamizade, M. J., Khlaifia, A., Skaleka, A., Lopez-Canul, M., Torres-Berrio, A., Bermudez, S., Rurak, G. M., et al. (2021) · Nature · doi:10.1038/s41586-020-03047-0 · Cited by 144
Caddy, C., Giaroli, G., White, T. P., Shergill, S. S., & Tracy, D. K. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125313507739 · Cited by 138
Quiroz, J. A., Tamburri, P., Deptula, D., Banken, L., Beyer, U., Rabbia, M., Parkar, N., Fontoura, P., & Santarelli, L. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.0838 · Cited by 133 · cited 1×
“The 9-week study included 6 weeks of double-blind treatment and 3 weeks of follow-up [114].”
MethodMoskal, J. R., Burch, R., Burgdorf, J. S., Kroes, R. A., Stanton, P. K., Disterhoft, J. F., & Leander, J. D. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.852536 · Cited by 131
Fogaça, M. V., Wu, M., Li, C., Li, X.-Y., Picciotto, M. R., & Duman, R. S. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-00916-y · Cited by 129 · cited 1×
“The greatest attention has been paid to the last of these hypotheses—the inhibition of NMDA receptors on GABAergic interneurons; indeed, a recent preclinical study found that inhibition of cortical GABAergic interneurons was necessary as well as sufficient to engender a rapid antidepressant-like response in mice [27].”
BackgroundSanacora, G., Johnson, M. R., Khan, A., Atkinson, S. D., Riesenberg, R. R., Schronen, J. P., Burke, M. A., Zajecka, J. M., Barra, L., Su, H.-L., et al. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.224 · Cited by 120 · cited 2×
“A larger (n = 302), 6-week, phase IIb study of adjunctive repeated-dose lanicemine (50 mg and 100 mg) then found no separation from placebo on primary endpoint measures [97], though this may have been due to a large placebo effect (39%).”
BackgroundAcevedo-Diaz, E. E., Cavanaugh, G. W., Greenstein, D., Kraus, C., Kadriu, B., Zarate, C. A., & Park, L. T. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.11.028 · Cited by 113 · cited 1×
“In addition to these psychotomimetic/dissociative effects, (R,S)-ketamine also carries abuse liability and is associated with clinical side effects that include blood pressure changes, cognitive effects, risk of cystitis and other chronic bladder issues, and hepatotoxicity (though the latter two are less common at the…”
BackgroundSelf-citationThe role of eEF2 pathway in learning and synaptic plasticity
Taha, E., Gildish, I., Gal-Ben-Ari, S., & Rosenblum, K. (2013) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2013.04.015 · Cited by 111 · cited 1×
“AMPA activation is also known to modulate BDNF, tropomyosin receptor kinase B (TrkB), glycogen synthase kinase 3 (GSK3), eEF2 [31], and mammalian target of rapamycin complex 1 (mTORC1) to increase neuroplastic processes [32].”
BackgroundAdministration of ketamine for unipolar and bipolar depression
Kraus, C., Rabl, U., Vanicek, T., Carlberg, L., Popovic, A., Spies, M., Bartova, L., Gryglewski, G., Papageorgiou, K., Lanzenberger, R., et al. (2017) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2016.1254802 · Cited by 110 · cited 1×
“It should be noted that (R,S)-ketamine is associated with psychotomimetic effects that peak at about 40 min postinfusion, and it requires medical supervision during administration [63].”
BackgroundKetamine modulates fronto-striatal circuitry in depressed and healthy individuals
Mkrtchian, A., Evans, J. W., Kraus, C., Yuan, P., Kadriu, B., Nugent, A. C., Roiser, J. P., & Zarate, C. A. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-00878-1 · Cited by 110 · cited 1×
“In addition to these robust antidepressant effects, a single subanesthetic-dose (R,S)-ketamine infusion has also been found to have significant and rapid (1–4 h) anti-suicidal ideation effects [48–53], anti-anhedonic properties [54, 55], and therapeutic potential in other disorders such as posttraumatic stress disorde…”
BackgroundSelf-citationSwainson, J., McGirr, A., Blier, P., Brietzke, E., Richard-Devantoy, S., Ravindran, N., Blier, J., Beaulieu, S., Frey, B. N., Kennedy, S. H., et al. (2021) · The Canadian Journal of Psychiatry · doi:10.1177/0706743720970860 · Cited by 110
Lener, M. S., & Iosifescu, D. V. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12759 · Cited by 97 · cited 1×
“These findings fundamentally altered our underlying perceptions of the pathophysiology of depression and refocused research interest on the glutamatergic system as a source for possible treatments [13, 14] as well as new biomarkers for depression [15, 16].”
BackgroundControlled trial of d-cycloserine adjuvant therapy for treatment-resistant major depressive disorder
Heresco-Levy, U., Javitt, D. C., Gelfin, Y., Gorelik, E., Bar, M., Blanaru, M., & Kremer, I. (2006) · Journal of Affective Disorders · doi:10.1016/j.jad.2006.03.004 · Cited by 89 · cited 1×
“A small (n = 22), 6-week, placebo-controlled, crossover study of adjunctive DCS (250 mg/day) in individuals with TRD found that DCS reduced depressive symptoms, but the high placebo response rate precluded separation from placebo [101].”
BackgroundSestrin modulator NV-5138 produces rapid antidepressant effects via direct mTORC1 activation
Kato, T., Pothula, S., Liu, R.-J., Duman, C. H., Terwilliger, R., Vlasuk, G. P., Saiah, E., Hahm, S., & Duman, R. S. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126859 · Cited by 88 · cited 1×
“Animal models subsequently found that NV-5138 had rapid antidepressant effects [120, 121].”
BackgroundKetamine and the Future of Rapid-Acting Antidepressants
Riggs, L. M., & Gould, T. D. (2021) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-072120-014126 · Cited by 87 · cited 1×
“We refer the interested reader to a recent detailed review of relevant mechanisms [39].”
BackgroundMillan, M. (2002) · Current Drug Target -CNS & Neurological Disorders · doi:10.2174/1568007024606258 · Cited by 84 · cited 1×
“D-cycloserine (DCS) is a broad-spectrum antibiotic that, at doses > 100 mg/day, also acts as a functional NMDA glycine site modulator [99].”
BackgroundSynthesis and N-Methyl-d-aspartate (NMDA) Receptor Activity of Ketamine Metabolites
Morris, P. J., Moaddel, R., Zanos, P., Moore, C. E., Gould, T., Zarate, C. A., & Thomas, C. J. (2017) · Organic Letters · doi:10.1021/acs.orglett.7b02177 · Cited by 83 · cited 1×
“While (R)-ketamine is a less potent NMDA receptor inhibitor [30, 72], initial animal studies found that it had greater and longer-lasting antidepressant-like properties than esketamine [30, 73–75].”
Self-citationFogaça, M. V., Fukumoto, K., Franklin, T., Liu, R.-J., Duman, C. H., Vitolo, O. V., & Duman, R. S. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0501-x · Cited by 82 · cited 2×
“REL-1017 has demonstrated antidepressant activity in animal models [90].”
BackgroundCharacterization of an mGluR2/3 Negative Allosteric Modulator in Rodent Models of Depression
Campo, B., Kalinichev, M., Lambeng, N., Yacoubi, M. E., Royer-Urios, I., Schneider, M., Legrand, C., Parron, D., Girard, F., Bessif, A., et al. (2011) · Journal of Neurogenetics · doi:10.3109/01677063.2011.627485 · Cited by 78 · cited 1×
“Although both orthosteric and allosteric mGlu2/3 receptor modulators have been shown to exert antidepressant effects, the potency of allosteric modulators was found to be weaker than that of orthosteric antagonists [117].”
BackgroundBallard, E. D., Yarrington, J. S., Farmer, C. A., Lener, M. S., Kadriu, B., Lally, N., Williams, D., Machado-Vieira, R., Niciu, M. J., Park, L., et al. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.01.027 · Cited by 74 · cited 1×
“It is possible that identifying unidimensional constructs that can help parse the heterogeneity of depressive symptoms will ultimately create more refined rating scale scores to more successfully illuminate connections between specific symptoms and underlying pathophysiology [131].”
BackgroundSelf-citationSingle-Dose Ketamine Followed by Daily d-Cycloserine in Treatment-Resistant Bipolar Depression
Kantrowitz, J. T., Halberstam, B., & Gangwisch, J. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14l09527 · Cited by 72 · cited 1×
“An 8-week, open-label study then investigated adjunctive DCS (1000 mg/day) as a relapse prevention strategy after six intravenous (R,S)-ketamine infusions in 12 individuals with bipolar depression, only seven of whom completed the study [103].”
BackgroundDiscovery of NV-5138, the first selective Brain mTORC1 activator
Sengupta, S., Giaime, E., Narayan, S., Hahm, S., Howell, J., O’Neill, D., Vlasuk, G. P., & Saiah, E. (2019) · Scientific Reports · doi:10.1038/s41598-019-40693-5 · Cited by 72 · cited 1×
“NV-5138, an analog of the amino acid leucine, was developed as an mTORC1 activator and potential antidepressant [119].”
BackgroundPark, L. T., Kadriu, B., Gould, T. D., Zanos, P., Greenstein, D., Evans, J. W., Yuan, P., Farmer, C. A., Oppenheimer, M., George, J. M., et al. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa025 · Cited by 63 · cited 2×
“However, a recent phase II, double-blind, 2-week, placebo-controlled, crossover study of 19 participants with TRD found that AV-101 monotherapy (either 1080 mg/day or 1440 mg/day) did not improve participants’ overall depressive symptoms (as assessed by HAM-D total score) [109].”
BackgroundSelf-citationMilak, M. S., Rashid, R., Dong, Z., Kegeles, L. S., Grunebaum, M. F., Ogden, R. T., Lin, X., Mulhern, S. T., Suckow, R. F., Cooper, T. B., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.13211 · Cited by 63 · cited 1×
“For instance, one randomized, blinded, parallel design study of MDD participants treated with intravenous (R,S)-ketamine found that Glx response (as assessed by 1H-MRS) in the ventromedial prefrontal cortex was inversely correlated with (R,S)-ketamine dose and antidepressant effect; that is, greater antidepressant res…”
BackgroundMurrough, J. W., Stade, E., Sayed, S., Ahle, G., Kiraly, D. D., Welch, A., Collins, K. A., Soleimani, L., Iosifescu, D. V., & Charney, D. S. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.04.072 · Cited by 62 · cited 1×
“Finally, a prospective, open-label, 10-week, phase IIA clinical trial examined the tolerability and efficacy of Nuedexta in 20 participants with TRD, half of whom were receiving concomitant medications; the investigators found that response and remission rates were 45% and 35%, respectively, as measured by preand post…”
The emergence of new antidepressants for clinical use: Agomelatine paradox versus other novel agents
Fasipe, O. J. (2019) · IBRO Reports · doi:10.1016/j.ibror.2019.01.001 · Cited by 62 · cited 1×
“It was developed as an adjunctive therapy for TRD, appeared to be well tolerated, and did not cause psychotomimetic symptoms [107].”
MethodAntidepressant drugs act by directly binding to TRKB neurotrophin receptors
Casarotto, P. C., Girych, M., Fred, S. M., Kovaleva, V. D., Moliner, R., Enkavi, G., Biojone, C., Cannarozzo, C., Sahu, M. P., Kaurinkoski, K., et al. (2021) · NORA - Norwegian Open Research Archives · Cited by 61
Dextromethorphan as a potential rapid-acting antidepressant
Lauterbach, E. C. (2011) · Medical Hypotheses · doi:10.1016/j.mehy.2011.02.003 · Cited by 60 · cited 7×
“In addition, two recent studies suggest other theories that may underlie the mechanism of action of RAADs.”
BackgroundInfluentialLauterbach, E. C. (2012) · Medical Hypotheses · doi:10.1016/j.mehy.2012.02.012 · Cited by 54 · cited 7×
“In addition, two recent studies suggest other theories that may underlie the mechanism of action of RAADs.”
BackgroundInfluentialThe role of eEF2 kinase in the rapid antidepressant actions of ketamine
(2020) · Advances in Pharmacology · doi:10.1016/bs.apha.2020.04.005 · Cited by 52 · cited 1×
“The end result is dephosphorylation of eEF2, which leads to hippocampal de-suppression of brain-derived neurotrophic factor (BDNF) synthesis [29].”
BackgroundKelly, T., & Lieberman, D. Z. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.05.050 · Cited by 51 · cited 1×
“In a retrospective chart review of 77 participants with BD-II or BD not otherwise specified (BD-NOS), adding Nuedexta once or twice daily to a current medication regimen over 90 days significantly improved Clinical Global Impression (CGI) scale scores [85].”
MethodNovel Glutamatergic Treatments for Severe Mood Disorders
Park, M., Niciu, M. J., & Zarate, C. A. (2015) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-015-0050-5 · Cited by 40 · cited 1×
“These findings fundamentally altered our underlying perceptions of the pathophysiology of depression and refocused research interest on the glutamatergic system as a source for possible treatments [13, 14] as well as new biomarkers for depression [15, 16].”
BackgroundSelf-citationThe impact of sex as a biological variable in the search for novel antidepressants
Williams, A. V., & Trainor, B. C. (2018) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2018.05.003 · Cited by 40 · cited 1×
“Finally, given that there may be some sex-related differences in antidepressant efficacy and treatment response [133], including with (R,S)-ketamine and other NMDA modulators, clinical trials exploring sex differences are critical to establishing the potential therapeutic implications of this variable and to developin…”
BackgroundUmbricht, D., Niggli, M., Sanwald-Ducray, P., Deptula, D., Moore, R., Grünbauer, W., Boak, L., & Fontoura, P. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.18m12470 · Cited by 39
Bernstein, G., Davis, K., Mills, C., Wang, L., McDonnell, M., Oldenhof, J., Inturrisi, C., Manfredi, P. L., & Vitolo, O. V. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001035 · Cited by 37 · cited 1×
“REL-1017, an isomer of racemic methadone (d-methadone), is a non-competitive NMDA receptor antagonist [89, 90].”
BackgroundNeurobiological biomarkers of response to ketamine
(2020) · Advances in Pharmacology · doi:10.1016/bs.apha.2020.05.003 · Cited by 36 · cited 1×
“These findings fundamentally altered our underlying perceptions of the pathophysiology of depression and refocused research interest on the glutamatergic system as a source for possible treatments [13, 14] as well as new biomarkers for depression [15, 16].”
BackgroundSelf-citationLee, S.-Y., Chen, S.-L., Chang, Y.-H., Chen, S.-H., Chu, C.-H., Huang, S.-Y., Tzeng, N.-S., Wang, C.-L., Lee, I. H., Yeh, T. L., et al. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.01.024 · Cited by 35 · cited 1×
“That study found that dextromethorphan had no significant antidepressant effects, as assessed by mean Hamilton Depression Rating Scale (HAM-D) and Young Mania Rating Scale (YMRS) scores [82].”
MethodPothula, S., Liu, R.-J., Wu, M., Sliby, A., Picciotto, M. R., Banerjee, P., & Duman, R. S. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-00882-7 · Cited by 35 · cited 1×
“The rapid-acting antidepressant efficacy of AGN-241751, believed to function as an orally bioavailable small molecule NMDA receptor modulator and positive allosteric modulator [118], is currently being studied in a double-blind, placebocontrolled, phase II trial (NCT03726658) examining singledose versus multiple-dose…”
BackgroundA New Paradigm for Achieving a Rapid Antidepressant Response
Malhi, G. S., Morris, G., Bell, E., & Hamilton, A. (2020) · Drugs · doi:10.1007/s40265-020-01303-1 · Cited by 34 · cited 1×
“In contrast to standard antidepressant treatments whose delayed effects may take weeks to manifest, rapid-acting antidepressants (RAADs) such as (R,S)-ketamine may demonstrate almost immediate effects with maximal improvement observed within one day of initiating treatment [17].”
BackgroundZarate, C. A., & Machado-Vieira, R. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.249 · Cited by 33 · cited 1×
“Thus, the prevailing hypotheses suggest direct and indirect antagonism at the NMDA receptor as well as AMPA throughput modulation [5, 35, 36] as the neurochemical substrate of antidepressant effects.”
BackgroundSelf-citationKantrowitz, J. T., Milak, M. S., Mao, X., Shungu, D. C., & Mann, J. J. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16060735 · Cited by 23 · cited 1×
“Like (R,S)-ketamine, DCS administration (1000 mg) in healthy volunteers has been associated with acute (35 and 79–90 min) increases in Glx as measured by 1H-MRS [100].”
BackgroundNV-5138 as a fast-acting antidepressant via direct activation of mTORC1 signaling
Hasegawa, Y., Zhu, X., & Kamiya, A. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129702 · Cited by 20 · cited 1×
“Animal models subsequently found that NV-5138 had rapid antidepressant effects [120, 121].”
BackgroundUnderstanding the Clinical Effects and Mechanisms of Action of Neurosteroids
Kleinman, R. A., & Schatzberg, A. F. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20020134 · Cited by 18 · cited 1×
“Brexanolone (Zulresso), a neurosteroid derivative of allopregnanolone, acts as a positive allosteric modulator of GABAA receptor function [122]; in contrast to benzodiazepines, positive allosteric modulators bind and trigger the GABAA receptor to open more frequently or for longer periods, but they do not work indepen…”
BackgroundPatel, W., Rimmer, L. J., Smith, M., Moss, L., Smith, M. A., Snodgrass, H. R., Pirmohamed, M., Alfirevic, A., & Dickens, D. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00727 · Cited by 18 · cited 1×
“Another recent study explored potential mechanisms for this lack of conversion and found that co-administration of probenecid with 4-Cl-KYN led to dose-dependent increases in 7-Cl-KYNA concentrations by as much as ~ 800-fold in the prefrontal cortex of rats, suggesting a path forward for humans with depression [110].”
BackgroundMessias, E., & Everett, B. L. (2012) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.12l01400 · Cited by 17 · cited 1×
“Nuedexta was also found to have antidepressant effects in a case report describing a depressed patient with emotional lability [84].”
BackgroundmGlu2/3 receptor as a novel target for rapid acting antidepressants
Chaki, S. (2020) · Advances in pharmacology · doi:10.1016/bs.apha.2020.04.001 · Cited by 10 · cited 1×
“In preclinical studies, mGlu2/3 receptor inhibition elicits rapid antidepressant effects that resemble (R,S)-ketamine’s effects in rodents [115].”
BackgroundA phase I study of d-methadone in patients with chronic pain
Moryl, N., Tamasdan, C., Tarcatu, D., Thaler, H. T., Correa, D. D., Steingart, R. H., Payne, R., & Obbens, E. A. M. T. (2016) · Journal of Opioid Management · doi:10.5055/jom.2016.0311 · Cited by 8 · cited 1×
“In human trials, after a small, phase I, open-label study found that adjunctive use of REL-1017 effectively reduced pain in eight chronic pain sufferers [91], REL1017 was subsequently developed as a rapid-acting oral agent for the treatment of depression as well as neuropathic pain; it subsequently received FDA Fast-T…”
BackgroundZarate, C. A. (2021) · The Canadian Journal of Psychiatry · doi:10.1177/07067437211004023 · Cited by 5
Self-citation
Research works printed but not linked: 3
- NeuroRx. NeuroRx: Phase 3 drug for suicidal bipolar depression to present at BIO CEO conference. February 10, 2020. 2020. <https://www.prnewswire.com/news-releases/neurorx-phase-3-drug-for-suicidal-bipolar-depression-to-present-at-bio-ceo-conference-301001882.html>. Accessed 12 Aug 2020.
- Paterson B, Fraser H, Wang C, Marcus R. A randomized, double-blind, placebo-controlled, sequential parallel study of CERC-301 in the adjunctive treatment of subjects with severe depression and recent active suicidal ideation despite antidepressant treatment. National Network of Depression Centers Annual Conference; 2015 November 5–6; Ann Arbor, Michigan; 2015. <http://c.eqcdn.com/_2a1b537df6a6e1398b6806c9b30635ad/cerecor/db/322/603/file/Poster+-+Study+Clin301-201_FINAL.pdf>. Accessed 12 June 2020. [[Google Scholar](https://scholar.google.com/scholar_lookup?title=National%20Network%20of%20Depression%20Centers%20Annual%20Conference;%202015%20November%205%E2%80%936&author=B%20Paterson&author=H%20Fraser&author=C%20Wang&author=R%20Marcus&publication_year=2015&)]
- Sage Therapeutics. Sage announces pivotal Phase 3 trial status for SAGE-217 in major depressive disorder and postpartum depression based on FDA breakthrough therapy meeting. 2018. <https://investor.sagerx.com/news-releases/news-release-details/sage-announces-pivotal-phase-3-trial-status-sage-217-major>. Accessed 12 June 2020.
Cited by
New and emerging approaches to treat psychiatric disorders
Scangos, K. W., State, M. W., Miller, A. H., Baker, J. T., & Williams, L. M. (2023) · Nature Medicine · doi:10.1038/s41591-022-02197-0 · Cited by 179
Ketamine Treatment for Depression: A Review
Yavi, M., Lee, H., Henter, I. D., Park, L. T., & Zarate, C. A. (2022) · Discover Mental Health · doi:10.1007/s44192-022-00012-3 · Cited by 161
Self-citationGut-Brain Axis: Role of Microbiome, Metabolomics, Hormones, and Stress in Mental Health Disorders
Verma, A., Inslicht, S. S., & Bhargava, A. (2024) · Cells · doi:10.3390/cells13171436 · Cited by 161
“…hypotheses for mood disorders depicting a complex system where multiple mechanisms are involved, including dysfunction of different signaling pathway systems within neurons, including glutaminergic [69,70], norepinephrine [71], protein kinase C signaling [72], or our innate immune system [73].”
BackgroundNovel drug developmental strategies for treatment‐resistant depression
Borbély, É., Simon, M., Fuchs, E., Wiborg, O., Czéh, B., & Helyes, Z. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15753 · Cited by 106
“Furthermore, the ketamine metabolite (2R,6R)hydroxynorketamine is also involved in a Phase I study (NCT04711005), because it can evoke antidepressant effects through the activation of AMPA receptors (Henter et al., 2021).”
BackgroundCorrell, C. U., Solmi, M., Cortese, S., Fava, M., Højlund, M., Kraemer, H. C., McIntyre, R. S., Pine, D. S., Schneider, L. S., & Kane, J. M. (2023) · World Psychiatry · doi:10.1002/wps.21056 · Cited by 109
Metadata
- Authors
- Henter, I. D., Park, L. T., & Zarate, C. A.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Zarate, Carlos A.
- Venue
- CNS Drugs
- Published
- 2021-04-26
- Volume
- 35
- Issue
- 5
- Pages
- 527-543
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- PMC
- PMC8201267
- OpenAlex
- W3157093408
- Cited by
- 142
- References
- 127
- Citations by year
- 2026: 19 · 2025: 20 · 2024: 34 · 2023: 28 · 2022: 29 · 2021: 12
- FWCI
- 3.29
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- CNS Drugs (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health (ZIAMH002857)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- mood disorders, major depressive disorder, bipolar depression, ketamine, esketamine, hydroxynorketamine, dextromethorphan, D-cycloserine, NMDA receptor antagonists, rapid antidepressant response, antidepressant resistance
- MeSH terms
- Animals, Antidepressive Agents, Bipolar Disorder, Major Depressive Disorder, Humans, Receptors, Glutamate, Excitatory Amino Acid Agents, Glutamic Acid, Mood Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.